EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in proteomics in diffuse large B‑cell lymphoma (Review)

Zihan Guo, Chenchen Wang, Xinyi Shi, Zixuan Wang, Jingyi Tao, Jiaying Ma, Lintao Bi

Oncology Reports · 2024

DOI: 10.3892/or.2024.8746 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Reports, 2024. Verfasst von Zihan Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proteomics, Drug Resistance, Neoplasm, Tumor Microenvironment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‑cell lymphoma (DLBCL) is the most common pathological type of non‑Hodgkin's lymphoma. Although the development of monoclonal antibodies, small‑molecule‑targeted drugs and novel chemotherapeutic agents, and the increased use of immunotherapy have markedly improved the outcomes of DLBCL, ~40% of patients cannot be cured following the use of standardized first‑line treatment. In addition, the specific mechanisms of drug resistance and potential factors associated with a poor prognosis in these patients remain unclear. Proteomics research is used to determine potential associations between changes in DLBCL protein expression levels and different stages of disease occurrence and development. Proteomics may aid in the identification of novel molecular mechanisms and drug resistance mechanisms, through identifying multiple associated proteins and monitoring changes in expression levels. Thus, proteomics research may exhibit potential in the development of therapeutic targets and in improving prognostic evaluation in patients with DLBCL. The present study aimed to review the use of proteomic methods for the investigation of DLBCL, including the mechanisms underlying disease progression and drug resistance in DLBCL, and the function of the tumor microenvironment in lymphoma growth. The present review also demonstrated the potential of proteomic‑guided therapeutic strategies for DLBCL and discussed the synergistic benefits of using proteomic methods in DLBCL research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseProteomicsDrug Resistance, NeoplasmTumor MicroenvironmentHumansPrognosisBiomarkers, TumorDisease Progression

Stichwörter der Autor:innen

diagnosisdiffuse large B‑cell lymphomadrug resistancemulti‑omicsprognosisproteomicstreatmenttumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology and Oncology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.

Zitieren

APA

Guo, Z., Wang, C., Shi, X., Wang, Z., Tao, J., Ma, J., & Bi, L. (2024). Advances in proteomics in diffuse large B‑cell lymphoma (Review). Oncology Reports. https://doi.org/10.3892/or.2024.8746

Vancouver

Guo Z, Wang C, Shi X, Wang Z, Tao J, Ma J, et al. Advances in proteomics in diffuse large B‑cell lymphoma (Review). Oncology Reports. 2024. doi:10.3892/or.2024.8746

BibTeX
@article{Guo2024,
  author = {Guo, Zihan and Wang, Chenchen and Shi, Xinyi and Wang, Zixuan and Tao, Jingyi and Ma, Jiaying and Bi, Lintao},
  title = {Advances in proteomics in diffuse large B‑cell lymphoma (Review)},
  journal = {Oncology Reports},
  year = {2024},
  doi = {10.3892/or.2024.8746}
}
Kostenlos starten →